Quarterly ResultMay 7, 2026, 08:03 AM
Prime Medicine on track for H1 2026 IND/CTA filings; cash into 2027
AI Summary
Prime Medicine, Inc. reported its first-quarter 2026 financial results and provided a business update, highlighting significant pipeline progress. The company remains on track to file IND/CTA applications for PM577 in Wilson Disease in H1 2026 and PM647 in AATD mid-2026, with initial clinical data from both programs anticipated in 2027. Prime Medicine also announced the appointment of Svetlana Makhni as Chief Financial Officer and reported a cash position of $149.2 million as of March 31, 2026, providing a cash runway into 2027.
Key Highlights
- On track to file IND/CTA for PM577 (Wilson Disease) in H1 2026 and PM647 (AATD) mid-2026.
- Initial clinical data from PM577 and PM647 programs expected in 2027.
- Continued regulatory dialogue with FDA for BLA filing of PM359 (CGD).
- Appointed Svetlana Makhni as Chief Financial Officer in April 2026.
- Cash, cash equivalents, investments, and restricted cash were $149.2 million as of March 31, 2026.
- Cash runway expected into 2027 based on current operating plans.
- R&D expenses decreased to $34.1 million for Q1 2026 from $40.6 million in Q1 2025.
- Net loss was $49.1 million for Q1 2026, compared to $51.9 million for Q1 2025.